Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma

This study is being done to find out if this approach (taking botensilimab and balstilimab) is better or worse than the usual approach for colorectal adenocarcinoma that cannot be removed by surgery. The usual approach is defined as care most people get for colorectal adenocarcinoma that cannot be removed by surgery and that has become resistant to treatment with available therapies. The usual approach for patients who are not in a study is supportive care with drugs and other treatments that may help to make them feel better or may improve their quality of life. This treatment is known as "best supportive care." Although patients with best supportive care can feel better for some months, the cancer usually continues to grow.